Poziotinib, an oral pan‐HER inhibitor, due to its compact structure and flexible nature, has shown superior efficacy over approved EGFR TKIs in both in vitro and PDX models of EGFR Exon20ins–mutant NSCLC.122. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.